Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ductal Carcinoma In Situ: early-phase trial registry
8 of 16 indexed Ductal Carcinoma In Situ trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 8 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Ductal Carcinoma In Situ: 16 US clinical trials tracked, 8 recruiting.
Ductal Carcinoma In Situ is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Xoft, running 2 of these trials.
Enrollment posture brief
Registry condition ductal-carcinoma-in-situ
OPEN 8 | RECR 50% | LATE 1 | EARLY 4 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Ductal Carcinoma In Situ lists 8 open slots (50% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ductal Carcinoma In Situ on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ductal Carcinoma In Situ is recruiting above its size-band peers.
8 of 16 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Ductal Carcinoma In Situ trials is spread across many organizations.
Xoft accounts for 2 of 16 trials (12.5%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Ductal Carcinoma In Situ enrolment sits around 100 participants.
Median target enrolment is 100 among the 16 trials that report a genuine target (sentinel values excluded). 8 of those (50%) plan for fewer than 100 participants.
-
Ductal Carcinoma In Situ research is mostly interventional.
13 interventional and 3 observational studies make up this index (81.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
NCT06075953
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
Thomas Jefferson University
NCT07478016
Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)
RPCR
NCT04985032
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
UNC Lineberger Comprehensive Cancer Center
NCT06902311
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
University of Florida
NCT06903468
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
Finn, Olivera, PhD
NCT06218303
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
Glendale Adventist Medical Center d/b/a Adventist Health Glendale
NCT05218044
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
Barbara Ann Karmanos Cancer Institute
NCT07095114
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
Xoft
NCT01644669
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS
Alliance Foundation Trials
NCT02926911
Intraoperative Radiation Therapy (IORT) in DCIS
Columbia University
NCT03216421
Ruxolitinib for Premalignant Breast Disease
Julie Nangia
NCT02928978
Breast MRI as a Preoperative Tool for DCIS
Memorial Sloan Kettering Cancer Center
NCT00605982
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Xoft
NCT00742222
Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging
Dartmouth-Hitchcock Medical Center
NCT01060085
Living Well After Breast Surgery
University of Texas at Austin
NCT03834532
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Ductal Carcinoma In Situ records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ductal Carcinoma In Situ trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ductal Carcinoma In Situ page
16 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Ductal Carcinoma In Situ trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Xoft sponsors the most Ductal Carcinoma In Situ trials on record, review their full trial history before evaluating a specific study. See Xoft's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ductal Carcinoma In Situ condition card totals 16 registered trials; most-linked intervention Intracavitary accelerated partial breast irradiation; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.